Tim Illidge
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment 126
- Oncology top 0.2%
- CAR-T cell therapy research 35
- Cancer Immunotherapy and Biomarkers 33
- Viral-associated cancers and disorders 24
- Genetics top 0.5%
- Immunology top 0.5%
- Immunotherapy and Immune Responses 30
- Neurology top 0.5%
-
- Monoclonal and Polyclonal Antibodies Research 35
-
- Cutaneous lymphoproliferative disorders research 30
-
- Lung Cancer Treatments and Mutations 29
- Co-authors
- Jamie HoneychurchSimon J. DovediEleanor J. CheadleMark S. CraggLena SpechtRobert W. WilkinsonJekaterina ĒrenpreisaIan J. Stratford
- Journals
- Blood (42 papers)Journal of Clinical Oncology (17 papers)British Journal of Haematology (14 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Tim Illidge
211 papers receiving 10.8k citations
Hit Papers
Peers
Comparison fields: 5 of 133
- Pathology and Forensic Medicine 4.8k
- Oncology 5.6k
- Genetics 1.6k
- Immunology 2.5k
- Neurology 1.5k
Countries citing papers authored by Tim Illidge
This map shows the geographic impact of Tim Illidge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Illidge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Illidge more than expected).
Fields of papers citing papers by Tim Illidge
This network shows the impact of papers produced by Tim Illidge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Illidge. The network helps show where Tim Illidge may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tim Illidge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2022 | 16 | |
| 3 | 2021 | 43 | |
| 4 | 2021 | 17 | |
| 5 | 2020 | 8 | |
| 6 | 2017 | 263 | |
| 7 | A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS | 2017 | 1 |
| 8 | 2017 | 3 | |
| 9 | 2016 | 44 | |
| 10 | Real-world effectiveness of brentuximab vedotin vs other treatments in patients with relapsed/refractory Hodgkin lymphoma post autologous stem-cell transplantation. | 2016 | 5 |
| 11 | Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockadebreakdown → | 2014 | 974 |
| 12 | Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. | 2012 | 8 |
| 13 | 2011 | 222 | |
| 14 | Comparison of dosimetric approaches for Non-Hodgkin lymphoma in radioimmunotherapy | 2010 | 1 |
| 15 | Dosimetry for fractionated ZevalinTM treatment as an initial therapy of follicular lymphoma. | 2010 | 1 |
| 16 | 2009 | 0 | |
| 17 | Changes in serological biomarkers (BM) of cell death during chemotherapy (CT) in patients with lymphoma | 2008 | 1 |
| 18 | 2007 | 8 | |
| 19 | Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL) | 2005 | 7 |
| 20 | 2004 | 3 |
About Tim Illidge
Tim Illidge is a scholar working on Pathology and Forensic Medicine, Oncology and Dermatology, having authored 218 papers that have together received 11.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (126 papers), Monoclonal and Polyclonal Antibodies Research (35 papers), CAR-T cell therapy research (35 papers), Cancer Immunotherapy and Biomarkers (33 papers), Immunotherapy and Immune Responses (30 papers), Cutaneous lymphoproliferative disorders research (30 papers), Lung Cancer Treatments and Mutations (29 papers) and Viral-associated cancers and disorders (24 papers). The work is most often cited by research in Pathology and Forensic Medicine (4.8k citations), Oncology (5.6k citations) and Genetics (1.6k citations). Tim Illidge has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Jamie Honeychurch, Simon J. Dovedi, Eleanor J. Cheadle, Mark S. Cragg, Lena Specht, Robert W. Wilkinson, Jekaterina Ērenpreisa, Ian J. Stratford, Joachim Yahalom and Peter Hoskin. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.